Form 4: Precision Biosciences Director Plans Future Stock Purchase

Precision Biosciences Director Stanley Frankel filed a Form 4 reporting a planned acquisition of 2,700 shares of common stock at $4.70 per share under a Rule 10b5-1 plan.

Summary

• Director Stanley Frankel of Precision Biosciences Inc. (DTIL) filed a Form 4 reporting a planned acquisition of common stock.
• The transaction, made pursuant to a Rule 10b5-1 plan, involves the purchase of 2,700 shares of common stock.
• The planned acquisition date is December 16, 2025, at a price of $4.70 per share.
• Following this planned transaction, Mr. Frankel's direct beneficial ownership will increase to 19,478 shares of Precision Biosciences common stock.

Sentiment

Score: 6

Explanation: The planned acquisition of shares by a director signals confidence in the company's future, although the transaction is scheduled for a future date under a 10b5-1 plan, making it a positive but not immediately impactful event.

Positives

• Director Stanley Frankel's planned purchase of 2,700 shares at $4.70 indicates confidence in the company's future prospects.
• The transaction is being made under a Rule 10b5-1 plan, which allows insiders to pre-arrange trades to avoid accusations of trading on material non-public information.

Risks

• The transaction is planned for a future date (December 16, 2025), and market conditions or the company's performance could change before then, potentially impacting the significance of this planned purchase.

Future Outlook

NA

Industry Context

This insider transaction reflects a director's planned investment in the company's equity, signaling individual confidence in Precision Biosciences' future, rather than a direct reflection of broader industry trends.

Related Party Transactions

• Director Stanley Frankel's planned purchase of 2,700 shares of Precision Biosciences common stock at $4.70 per share constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view the planned insider purchase as a positive signal of management's confidence in the company's valuation and future prospects.

Next Steps

• Execution of the planned purchase of 2,700 shares by Director Stanley Frankel on December 16, 2025.

Key Dates

Recommendation

The planned future purchase of shares by a director under a 10b5-1 plan suggests management confidence. However, as the transaction is not yet executed and market conditions can change, it serves as a positive indicator rather than a strong immediate catalyst for a 'buy' recommendation. Investors should monitor the actual execution of the trade and broader company performance.

Keywords

Precision Biosciences, DTIL, Stanley Frankel, Insider Trading, Stock Purchase, Director, Common Stock, SEC Form 4, 10b5-1 Plan